Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive
Tempus AI has entered into a $1.5 billion agreement to acquire cancer test manufacturer Personalis, triggering a decline in both companies' share prices.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Tempus AI is acquiring Personalis in a deal valued at $1.5 billion. The acquisition aims to integrate Personalis’s molecular residual disease technology into the existing AI-enabled precision oncology platform maintained by Tempus.
Coverage from Fierce Biotech, Business Wire, Barron's, Reuters, and Investor's Business Daily emphasizes the technical integration of cancer genomics and the immediate market reaction. Reporting highlights that shares for both companies fell following the announcement.
Future developments will depend on the closing process of the transaction and market performance. Coverage does not yet specify the expected timeline for completion or the specific factors driving the decline in share price.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 3h ago.
Quick answers
What is the value of the acquisition?
The deal is valued at $1.5 billion.
What is the primary goal of the purchase?
The acquisition is intended to integrate Personalis’s molecular residual disease technology into the Tempus AI precision oncology platform.
How did the stock market react?
Shares for both Tempus AI and Personalis declined following the announcement.
Coverage (7)
- Tempus AI is acquiring cancer-monitoring firm Personalis in a $1.5 billion stock deal qz.com · 16h ago
- Tempus AI to Buy Cancer-Tech Firm Personalis For $1.7 Billion Bloomberg.com · 16h ago
- Tempus buys out cancer genomics partner Personalis in $1.5 billion deal Fierce Biotech · 16h ago
- Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform Business Wire · 16h ago
- Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink Barron's · 16h ago
- Tempus to buy cancer test maker Personalis for $1.5 billion Reuters · 16h ago
- Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive Investor's Business Daily · 16h ago
Topics
Related trends
Creatine supplements may help halt cancer growth, study suggests
Recent research into creatine supplements has prompted conflicting reports regarding their potential impact on cancer growth and immune response.
Leading oncologist reveals 6 habits that could promote longevity and reduce your risk of chronic illness
A leading oncologist is shifting focus from traditional wellness trends toward unconventional longevity habits, including the consumption of ice cream.
Only 13% survive this cancer. A blood test just detected 90% of early cases
A new blood-based mRNA diagnostic test is showing potential in identifying early-stage pancreatic cancer, a condition with historically low survival rates.
Netflix Paid $587 Million for Ben Affleck’s AI Startup InterPositive
Netflix has confirmed the acquisition of Ben Affleck’s artificial intelligence startup, InterPositive, for $587 million.
Kids with deadliest brain cancers survive years after breakthrough cell therapy
An experimental autologous T cell therapy has led to multi-year survival in children previously diagnosed with terminal brain cancer.
California AG Rob Bonta says a CNN spin-off wouldn’t resolve Paramount–WBD lawsuit
California Attorney General Rob Bonta challenges the viability of a CNN spin-off as a solution to the ongoing Paramount and Warner Bros. merger litigation.